US Stocks
US Options
Emerging Asia
GBP Cash Savings
Charts & Tools
Paper Trading
Extended Hours
Wall Street Journal
TradingViewC
CGEN
Compugen
1.53
-0.07-4.38%After Hours: 1.520 -0.01 -0.65%17:30 12/12 EST
OPEN/PREV CLOSE1.600/1.600
TODAY RANGE1.495-1.600
VOL538.65K
MARKET CAP143.11M
52 WEEK RANGE1.130-2.660
AVG VOL (3M)398.75K
% TURNOVER0.58%
TURNOVER--
P/E (TTM)-5.1136
% RANGE6.56%
EPS(TTM)-0.2992
P/E(FORWARD)-4.9355
P/B3.265
BVPS0.4686
DIVIDEND--
P/S4.916
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP140.21M
SHARES OUTSTANDING93.54M
NEXT EARNINGS03/02-03/06
FREE FLOAT91.64M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·1d ago
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug
Benzinga·12/05 21:05
12 Health Care Stocks Moving In Friday's After-Market Session
TipRanks·11/11 13:05
Compugen (CGEN) Receives a Buy from Truist Financial
TipRanks·11/11 04:18
Compugen Reports Q3 2025 Results and Clinical Progress
TipRanks·11/11 00:14
Compugen’s Earnings Call: Strategic Focus Amid Financial Challenges
NASDAQ·11/10 13:15
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
TipRanks·11/10 12:28
Compugen Reports Q3 2025 Results and Advances Clinical Trials
TipRanks·11/10 12:23
Compugen reports Q3 EPS (7c), consensus (9c)
Seeking Alpha·11/10 12:10
Compugen GAAP EPS of -$0.07, revenue of $1.9M
PR Newswire·11/10 12:00
Compugen Reports Third Quarter 2025 Results
Seeking Alpha·11/09 23:00
Here are the major earnings before the open Monday
PR Newswire·11/04 12:00
Compugen to Participate in Stifel 2025 Healthcare Conference
TipRanks·10/27 23:48
Compugen’s COM701 Trial: A Potential Game-Changer in Ovarian Cancer Treatment
PR Newswire·10/27 11:00
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Seeking Alpha·10/27 08:01
Compugen Stock: Runway Into 2027 But Expensive
Same Industry
Name/Symbol
Change%
Price